At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 212 enrolled
Drug / intervention
BoostrixTM Poliobiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of GSK Biologicals' Boostrix™ Polio in Healthy Adults, 10 Years After a Booster Vaccination
In Brief
A Phase 4 clinical trial evaluating BoostrixTM Polio for Acellular Pertussis and 3 related conditions. Completed, enrolled 212 participants across 15 sites in 2 countries.
Detailed Summary
This study will evaluate the persistence of immune response against diphtheria, tetanus, pertussis and poliomyelitis in healthy adults, 10 years after a booster dose, and also assess the immunogenicity and safety of another booster dose of BoostrixTM Polio.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcellular Pertussis, Poliomyelitis, Diphtheria, Tetanus
CountriesFrance, Germany
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartApr 2011
Primary CompletionMar 2012
TodayJul 2026
First PostedMar 28, 2011
Enrollment StartApr 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 15.3 years ago
Interventions
BoostrixTM Poliobiological
Single dose, intramuscular administration.